Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Sunkara, G.; Sabo, R.; Wang, Y.; He, Y.L.; Campestrini, J.; Rosenberg, M.; Howard, D.; Dole, W.P.
    Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers (2007), J. Clin. Pharmacol., 47, 1152-1158.
    View publication on PubMed

Application

Application Comment Organism
medicine vildagliptin is a potent and selective dipeptidyl peptidase IV inhibitor in development for the treatment of type 2 diabetes that improves glycemic control by enhancing alpha- and beta-cell responsiveness to glucose. Vildagliptin displays approximately dose-proportional pharmacokinetics over the 25-mg to 200-mg dose range, and administration with food has no clinically relevant effect on vildagliptin pharmacokinetics Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
vildagliptin
-
Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Synonyms

Synonyms Comment Organism
dipeptidyl peptidase IV
-
Homo sapiens